DOCKET NO.: 46598-5005-US-01 (99-01; WO/386)

Application No.: 09/868,196 Office Action Dated: July 28, 2005 PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application. Listing of Claims:

1-44. Canceled

45. (Currently amended) A method of treating metastatic elinically manifest mammary tumors in postmenopausal women, comprising the steps of:

- a) detecting a <u>metastatic</u> clinically manifest mammary tumor in a postmenopausal woman;
 - b) administering to the postmenopausal woman a first dose of hCG; and
- c) administering to the postmenopausal woman one or more subsequent doses of hCG, wherein the first dose and the subsequent doses of hCG are administered in an amount and over a period of time effective to inhibit proliferation of mammary tumor cells, thereby treating the metastatic elinically manifest mammary tumors.

46-62. Canceled.

63. (Currently amended) The method of claim 48, combined with at least one other treatment for metastatic elinically manifest mammary tumors.

3 64. (Previously presented) The method of claim 65, wherein the at least one other treatment is surgery or chemotherapy.

45. (Previously presented) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66-69. Canceled.


70. (Previously presented) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

Page 2 of 12

DOCKET NO.: 46598-5005-US-01 (99-01; WO/386) Application No.: 09/868,196

Office Action Dated: July 28, 2005

PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116



72. (Previously presented) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

(Previously presented) The method of claim 45, wherein the one or more subsequent doses of hCG are administered every second day following administration of the first dose.

(Previously presented) The method of claim 48, wherein the one or more subsequent doses of hCG are administered three times each week following administration of the first dose.

(Previously presented) The method of claim 43, wherein the one or more subsequent doses of hCG are administered for several weeks following administration of the first dose.

(Previously presented) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

(Previously presented) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (Previously presented) The method of claim 48, wherein the hCG is administered in combination with Type 1 interferon.

79. Canceled.

DOCKET NO.: 46598-5005-US-01 (99-01; WO/386)

Application No.: 09/868,196 Office Action Dated: July 28, 2005 PATENT REPLY FILED UNDER EXPEDITED PROCEDURE PURSUANT TO 37 CFR § 1.116

80. (Previously presented) The method of claim 45, wherein the hCG is recombinant hCG.

81-103. Canceled.